文献速递创伤骨科骨质疏松与代谢性骨病

日本髋部骨折术后出院时抗骨质疏松药物处方的全国医保报销政策影响:间断时间序列分析

Impact of a national reimbursement policy on anti-osteoporosis medication prescription at discharge after hip-fracture surgery in Japan: an interrupted time-series analysis.
PubMed 文献 · Osteoporos Int · 2025-10-15

该研究基于日本爱知县172家急性期医院的回顾性队列,纳入2015年第一季度至2023年第四季度接受髋部骨折手术的≥65岁成人78,224例,采用分段间断时间序列回归分析2022年4月引入的二次骨折预防持续管理费(SFP-CMF)对出院时抗骨质疏松药物处方的影响。结果显示,政策引入后处方率立即增加20.8个百分点(95%CI 14.9-26.7;p<0.001),后续7个季度斜率增加17.8个百分点/年(95%CI 13.6-22.1;p<0.001),增益主要来自口服药物(维生素D类似物、双膦酸盐),注射剂短暂上升后下降。

要点

  • 2022年日本SFP-CMF政策实施后,髋部骨折术后出院时抗骨质疏松药物处方率立即增加20.8个百分点(95%CI 14.9-26.7;p<0.001)。
  • 政策后7个季度(1.75年)内处方率年斜率增加17.8个百分点/年(95%CI 13.6-22.1;p<0.001),主要归因于口服药物。
  • 注射剂处方短暂上升后下降,作者认为需监测给药途径特异性实施情况,并需进一步评估出院后各阶段及骨折结局。

核心结论

  • 将适度的、分阶段的财务激励嵌入全国医保报销目录后,髋部骨折术后出院时抗骨质疏松药物处方持续大幅增加,且主要为口服药物。
  • 注射剂处方的同步下降提示给药途径特异性实施值得监测,并需进一步评估出院后各阶段及骨折结局。

研究设计与样本

  • 回顾性队列研究,使用日本诊断程序组合按日付费系统(DPC/PDPS)覆盖爱知县172家急性期医院的数据。
  • 纳入2015年第一季度至2023年第四季度接受髋部骨折手术的≥65岁成人,共78,224例(干预前59,547例,干预后18,677例)。
  • 采用分段间断时间序列回归分析2022年4月引入的二次骨折预防持续管理费(SFP-CMF)与任何抗骨质疏松药物季度起始率水平和斜率变化的关系,并对给药途径(口服 vs 注射)作简要描述。

主要发现

  • 政策实施前,出院处方缓慢增加(+1.4个百分点/年;95%CI 1.0-1.8;p<0.001)。
  • SFP-CMF引入后,处方率立即变化+20.8个百分点(95%CI 14.9-26.7;p<0.001)。
  • 政策后7个季度(1.75年)期间,斜率变化为+17.8个百分点/年(95%CI 13.6-22.1;p<0.001)。
  • 大部分增益归因于口服药物(维生素D类似物、双膦酸盐);注射剂短暂上升后下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,注射剂处方的同步下降提示给药途径特异性实施值得监测,并需进一步评估出院后各阶段及骨折结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A 2022 pay-for-performance fee in Japan increased the rate of post-hip-fracture osteoporosis treatment (primarily oral agents) by 20.8 percentage points and tripled the annual uptake trend in an interrupted time-series analysis of 78,224 patients. Financial incentives embedded within national fee schedules may help close gaps in secondary fracture prevention. PURPOSE: Although osteoporosis treatment is essential for preventing secondary fractures, many patients remain untreated after hip-fracture surgery. Accordingly, Japan introduced a three-stage reimbursement add-on, the Secondary Fracture Prevention Continuous Management Fee (SFP-CMF) in April 2022. We assessed its real-world impact on anti-osteoporosis medication prescription at discharge. METHODS: Using data from Japan's Diagnosis Procedure Combination Per-Diem Payment System (DPC/PDPS) covering 172 acute-care hospitals in Aichi Prefecture, we identified a retrospective cohort of adults aged ≥ 65 years who underwent hip-fracture surgery between the first quarter of 2015 and fourth quarter of 2023. Quarterly initiation rates for any osteoporosis medication were analyzed using segmented interrupted time-series regression to estimate changes in level and slope associated with the 2022 reimbursement policy, with brief route-specific description (oral vs. injectable). RESULTS: We included 78,224 patients (59,547 pre-intervention; 18,677 post-intervention). Before the policy, discharge prescription increased slowly (+ 1.4 percentage points [pp]/year; 95% CI 1.0-1.8; p < 0.001). SFP-CMF introduction was followed by an immediate + 20.8 pp change (95% CI 14.9-26.7; p < 0.001) and a + 17.8 pp/year post-intervention slope (95% CI 13.6-22.1; p < 0.001) over the subsequent 7-quarter (1.75-year) period. Most gains were attributable to oral agents (vitamin D analogs, bisphosphonates); injectables rose briefly but subsequently declined. CONCLUSION: Embedding a modest, stage-specific financial incentive within the national fee schedule produced a sustained large increase in anti-osteoporosis medication prescription at discharge after hip fracture, predominantly for oral agents. The concomitant decline in injectables suggests that route-specific implementation merits monitoring, and further evaluation across post-discharge phases and fracture outcomes is warranted.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Takegami Y, Imaizumi T, Sato K, et al. Impact of a national reimbursement policy on anti-osteoporosis medication prescription at discharge after hip-fracture surgery in Japan: an interrupted time-series analysis. Osteoporos Int. 2025. PMID: 41091162. doi:10.1007/s00198-025-07721-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。